Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00890500 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.
A Phase 1 study, sponsored by Fate Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00890500 is a Phase 1 study that has completed, run by Fate Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT00890500, a Phase 1 study, has completed, sponsored by Fate Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the safety and efficacy of a reduced intensity conditioning regimen during a double umbilical cord blood unit transplant with one of the cord blood units modulated with ProHema.
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Sirolimus
- DRUG Tacrolimus
- DRUG Antithymocyte Globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-01 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00890500
The ClinicalTrials.gov registry entry for NCT00890500 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fate Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT00890500 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00890500 about?
NCT00890500 is a clinical study titled "Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.". The purpose of this research study is to determine the safety and efficacy of a reduced intensity conditioning regimen during a double umbilical cord blood unit transplant with one of the cord blood units modulated with ProHema.
What is the current status of trial NCT00890500?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2011-01. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00890500?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Sirolimus (DRUG), Tacrolimus (DRUG), Antithymocyte Globulin (DRUG).
Who is sponsoring clinical trial NCT00890500?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.